Data for: Stopping Oral Steroid Sparing Agents at Initiation of Rituximab in Myasthenia Gravis
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://data.mendeley.com/datasets/srxmkft849
下载链接
链接失效反馈官方服务：
资源简介：
Data set 1.
应用场景：
创建时间：
2019-07-08
相关数据集
Data for: Stopping Oral Steroid Sparing Agents at Initiation of Rituximab in Myasthenia Gravis
Data set 1.
Mendeley Data2019-07-08 更新30
Data from: Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab
Introduction: Autoantibodies (autoAbs) against desmoglein-1 (DSG1) and desmoglein-3 (DSG3) have conventionally been studied and well accepted in the pathogenesis of pemphigus vulgaris (PV) and foliace
DataCite Commons2022-11-04 更新70
Myasthenia Gravis Market
Report of Myasthenia Gravis Market is currently supplying a comprehensive analysis of many things which are liable for economy growth and factors which could play an important part in the increase of
IMR REPORTS00
Table_1_A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.docx
Background and PurposeTwo clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-spar
NIAID Data Ecosystem20
ASV tables of Myasthenia gravis (MG) and non-Myasthenia gravis
Myasthenia gravis (MG) is a neuromuscular junction disease with a complex pathophysiology and clinical variation for which no clear biomarker has been discovered. We hypothesized that because changes
NIAID Data Ecosystem10
